Patent · US Active

Anti-C5a binding moieties with high blocking activity

US10774136B2 · kind B2 · utility

5Cited by

4References

10Claims

0Family size

Assignee

InflaRx GmbH · DE

Inventors

Renfeng Guo · Ann Arbor, US
Niels Christoph Riedemann · Jena, DE
Yan Li · Tallahassee, US
Beifen Shen · Beijing, CN

Key dates

Filing date	Sep 16, 2016
Grant date	Sep 15, 2020
Priority date	—
Expiry date	Sep 16, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.